# US 2023/0416761 A1 · Targeted Protease Compositions and Uses Related Thereto

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0416761 A1
- Document ID: US20230416761A1
- Status: Published application
- Kind: A1
- Application number: 18/188,038
- Filed: 2023-03-22
- Published: 2023-12-28
- Earliest claimed: 2013-12-10
- Assignees: Emory University
- Applicants: Emory University
- Inventors: Lily Yang; Xiangxue Guo
- Web page: https://patentgrep.com/patent/US20230416761A1

## CPC

- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61K 49/0065: {the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle}
- A61P 35/00: Antineoplastic agents
- C12N 9/50: Proteinases {, e.g. Endopeptidases (3.4.21-3.4.25)}
- C12N 9/96: Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12Y 304/00: Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C07K 2319/01: containing a localisation/targetting motif
- C12N 2810/00: Vectors comprising a targeting moiety
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

This disclosure relates to targeted protease compositions and uses related thereto. In certain embodiments, the disclosure relates to nanoparticles wherein a targeting molecule is linked to the nanoparticle and wherein a catalytic domain of a protease is linked to the nanoparticle. In certain embodiments, the targeting molecule and the catalytic domain are within a single polypeptide sequence. In certain embodiments, the targeting molecule binds a molecule more highly expressed on cancer cells then non-cancerous cells, and the nanoparticles disclosed herein are used for the treatment of cancer by further attaching an anti-cancer agent to the nanoparticle or incorporating an anticancer agent within the nanoparticle.

## Claims

### Claim 1

A method of treating cancer comprising administering to a subject in need thereof an effective amount of a nanoparticle comprising an anticancer agent,
wherein the nanoparticle is conjugated to a fusion polypeptide comprising a targeting polypeptide and a protease polypeptide having a catalytic domain,
wherein the targeting polypeptide comprises the amino acid sequence of SEQ ID NO: 2,
wherein the protease polypeptide having a catalytic domain comprises the amino acid sequence motif depicted in SEQ ID NO: 5.

### Claim 2 (depends on 1)

The method of claim 1, wherein the protease polypeptide comprises SEQ ID NO: 3.

### Claim 3 (depends on 1)

The method of claim 1, wherein the fusion polypeptide comprises SEQ ID NO: 4.

### Claim 4 (depends on 1)

The method of claim 1, wherein the anticancer agent is doxorubicin.

### Claim 5 (depends on 1)

The method of claim 1, wherein the anticancer agent is gemcitabine.

### Claim 6 (depends on 1)

The method of claim 1, wherein the anticancer agent is cisplatin.

### Claim 7 (depends on 1)

The method of claim 1, wherein the cancer is breast cancer.

### Claim 8 (depends on 1)

The method of claim 1, wherein the cancer is triple negative breast.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cancer is pancreatic.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cancer is skin cancer.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cancer is head and neck cancer

### Claim 12 (depends on 1)

The method of claim 1, wherein the cancer is liver cancer.

### Claim 13 (depends on 1)

The method of claim 1, wherein the cancer is sarcoma.

### Claim 14 (depends on 1)

The method of claim 1, wherein the cancer is lung cancer.

### Claim 15 (depends on 1)

The method of claim 1, wherein the cancer is prostate cancer.
